Sugi Predict

Sugi Predict / Compounds / SCHEMBL367384

SCHEMBL367384

SCHEMBL367384

CC(C)C(=O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@@H]1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.65
▸ HINT1 P49773 5/20 0.55
▸ P2RY2 P41231 1/20 0.55
▸ P2RY4 P51582 1/20 0.55
▸ P2RY6 Q15077 1/20 0.55
▸ GSK3A P49840 2/20 0.50
▸ RPS6KA3 P51812 2/20 0.50
▸ MAPK14 Q16539 2/20 0.50
▸ TYMP P19971 1/20 0.49
▸ PNP P00491 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ NT5E P21589 2/20 0.47
▸ POLA1 P09884 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ PDE3A Q14432 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8622463 0.91 POLB (0.67) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL8622459 0.91 POLB (0.67) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL10532094 0.90 POLB (0.53) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL24852831 0.89 POLB (0.53) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL3751858 0.89 POLB (0.67) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL7562193 0.88 POLB (0.51) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL338650 0.88 POLB (0.70) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL16359949 0.88 POLB (0.70) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL5347882 0.88 POLB (0.63) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL766594 0.88 POLB (0.63) POLBHINT1P2RY2P2RY4P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114369123-A Efficient preparation method of 5' -aminodeoxynucleoside 山东明化新材料有限公司 2022-04-19 — — CN claimed
WO-2000075154-A2 PROTECTED NUCLEOSIDES ALLIEDSIGNAL INC. (US) 2000-12-14 — — WO claimed
US-12559517-B2 Oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2026-02-24 — — US disclosed
WO-2024122300-A1 PROCESSING LIQUID, CLEANING METHOD FOR OBJECT TO BE PROCESSED, AND METHOD FOR PRODUCING ELECTRONIC DEVICE 富士フイルム株式会社 2024-06-13 — — WO disclosed
US-20240117278-A1 TREATMENT LIQUID, CLEANING METHOD OF SEMICONDUCTOR SUBSTRATE, AND MANUFACTURING METHOD OF SEMICONDUCTOR ELEMENT FUJIFILM CORPORATION (JP) 2024-04-11 — — US disclosed
US-20240018442-A1 CLEANING LIQUID FOR SEMICONDUCTOR SUBSTRATE AND CLEANING METHOD FOR SEMICONDUCTOR SUBSTRATE FUJIFILM CORPORATION (JP) 2024-01-18 — — US disclosed
CN-114369123-B Efficient preparation method of 5' -amino deoxynucleoside 山东明化新材料有限公司 2023-09-29 — — CN disclosed
WO-2023182142-A1 COMPOSITION, SEMICONDUCTOR-ELEMENT MANUFACTURING METHOD, AND SEMICONDUCTOR-SUBSTRATE WASHING METHOD 富士フイルム株式会社 2023-09-28 — — WO disclosed
WO-2023176708-A1 CLEANING COMPOSITION AND SEMICONDUCTOR SUBSTRATE CLEANING METHOD 富士フイルム株式会社 2023-09-21 — — WO disclosed
WO-2023114547-A2 UNIVERSAL OLIGOMER SYNTHESIS AND SENSING PLATFORM AVERY DIGITAL DATA, INC. (US) 2023-06-22 — — WO disclosed
WO-2022255220-A1 PROCESSING SOLUTION, METHOD FOR CLEANING SEMICONDUCTOR SUBSTRATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR ELEMENT 富士フイルム株式会社 2022-12-08 — — WO disclosed
US-5166315-A Polynucleotides for genetic engineering ANTI-GENE DEVELOPMENT GROUP (US) 1992-11-24 — — US disclosed
WO-1992013561-A1 OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS PRO-NEURON, INC. (US) 1992-08-20 — — WO disclosed
WO-1992013869-A1 METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM GILEAD SCIENCES, INC. (US) 1992-08-20 — — WO disclosed
EP-0163529-B1 INSULIN PRECURSORS, PROCESS FOR THEIR PREPARATION AND PROCESS FOR PREPARING HUMAN INSULIN FROM SUCH INSULIN PRECURSORS NOVO NORDISK A/S (DK) 1991-08-21 — — EP disclosed
US-5021550-A Method for preventing deletion sequences in solid phase synthesis THOMAS JEFFERSON UNIVERSITY (US) 1991-06-04 — — US disclosed
EP-0427296-A1 Insulin precursors NOVO NORDISK A/S (DK) 1991-05-15 — — EP disclosed
EP-0135587-B1 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS SYNGENE, INC. (US) 1990-05-02 — — EP disclosed
EP-0202758-A1 Hybridization method and probes therefor ZENECA LIMITED (GB) 1986-11-26 — — EP disclosed
EP-0058954-A2 Tridecadeoxynucleotide, process for its preparation and the application Dr. Karl Thomae GmbH (DE) 1982-09-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559517-B2 Oligonucleotide manufacturing method POLL, IGF2BP1, POLI POLB 25/4885HINT1 2675/4885P2RY2 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.